[go: up one dir, main page]

MX2018005274A - Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. - Google Patents

Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.

Info

Publication number
MX2018005274A
MX2018005274A MX2018005274A MX2018005274A MX2018005274A MX 2018005274 A MX2018005274 A MX 2018005274A MX 2018005274 A MX2018005274 A MX 2018005274A MX 2018005274 A MX2018005274 A MX 2018005274A MX 2018005274 A MX2018005274 A MX 2018005274A
Authority
MX
Mexico
Prior art keywords
cells
methods
generating
immunotherapeutic
stem
Prior art date
Application number
MX2018005274A
Other languages
English (en)
Inventor
M Crooks Gay
S Seet Christopher
Montel-Hagen Amelie
Original Assignee
The Regents Of The Universtiy Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The Universtiy Of California filed Critical The Regents Of The Universtiy Of California
Publication of MX2018005274A publication Critical patent/MX2018005274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan métodos y una composición para la producción de células-T. También se proporcionan métodos terapéuticos usando las células T diseñadas; por ejemplo, en ciertos aspectos los métodos incluyen preparar composiciones de cultivos celulares tridimensionales que comprenden células estromales y células madre o progenitoras hematopoyéticas en un medio libre de suero para producir células T.
MX2018005274A 2015-10-30 2016-10-28 Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. MX2018005274A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562248931P 2015-10-30 2015-10-30
US201562265204P 2015-12-09 2015-12-09
US201662359456P 2016-07-07 2016-07-07
PCT/US2016/059375 WO2017075389A1 (en) 2015-10-30 2016-10-28 Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells

Publications (1)

Publication Number Publication Date
MX2018005274A true MX2018005274A (es) 2019-09-19

Family

ID=58631163

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005274A MX2018005274A (es) 2015-10-30 2016-10-28 Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
MX2024012982A MX2024012982A (es) 2015-10-30 2018-04-26 Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024012982A MX2024012982A (es) 2015-10-30 2018-04-26 Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t

Country Status (12)

Country Link
US (3) US11154573B2 (es)
EP (1) EP3368660A4 (es)
JP (2) JP6983771B2 (es)
KR (1) KR20180092951A (es)
CN (1) CN108463548B (es)
AU (2) AU2016343682A1 (es)
CA (1) CA3003145C (es)
IL (1) IL258899B2 (es)
MX (2) MX2018005274A (es)
SG (1) SG11201803419PA (es)
TW (2) TW202344686A (es)
WO (1) WO2017075389A1 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
US10927160B2 (en) * 2014-07-09 2021-02-23 The Regents Of The University Of California Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
IL258899B2 (en) 2015-10-30 2024-03-01 Univ California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells
CN116790476A (zh) 2016-05-05 2023-09-22 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP3534907A4 (en) 2016-11-04 2020-06-24 Children's Hospital Medical Center COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
WO2018111981A1 (en) * 2016-12-13 2018-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
AU2018272017B2 (en) * 2017-05-26 2021-11-04 Kite Pharma, Inc. Methods of making and using embryonic mesenchymal progenitor cells
JP7416629B2 (ja) * 2017-06-16 2024-01-17 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 免疫応答を増強するための物質および方法
CA3070579A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
KR101996218B1 (ko) * 2017-09-05 2019-10-01 주식회사 싸이토젠 Axl 기반 암환자 스크리닝 방법
JP7372910B2 (ja) 2017-09-20 2023-11-01 アメリカ合衆国 ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
TW201925782A (zh) * 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
KR102862251B1 (ko) * 2017-12-08 2025-09-22 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법을 위한 표현형 마커 및 관련 방법
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
WO2019145453A1 (en) 2018-01-28 2019-08-01 Universite De Geneve Arginase suppression for cancer treatment
KR102618231B1 (ko) 2018-02-16 2023-12-28 카이트 파마 인코포레이티드 변형된 만능성 줄기 세포, 및 제조 및 사용 방법
IL278044B2 (en) * 2018-04-19 2024-04-01 Baylor College Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
CN110499291B (zh) * 2018-05-16 2023-11-24 上海赛比曼生物科技有限公司 无血清培养制备嵌合抗原受体t细胞的方法
WO2019241400A1 (en) * 2018-06-12 2019-12-19 The Regents Of The University Of California Stem cell-engineered inkt cell-based off -the-shelf cellular therapy
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
SG11202100260QA (en) * 2018-07-13 2021-02-25 Univ Kyoto METHOD FOR PRODUCING γδ T CELLS
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
SG11202101455TA (en) * 2018-08-28 2021-03-30 Hutchinson Fred Cancer Res Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
US12428622B2 (en) 2018-09-12 2025-09-30 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
EP3853351A1 (en) 2018-09-19 2021-07-28 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
WO2020123015A1 (en) * 2018-10-01 2020-06-18 The Trustees Of Columbia University In The City Of New York Three-dimensional co-culture system for high-throughput testing of therapeutics and diagnostics
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) * 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN109762843A (zh) * 2018-12-29 2019-05-17 武汉波睿达生物科技有限公司 一种利用脐血来源的cd3阳性t细胞制备通用car-t细胞的方法
CN109652376B (zh) * 2019-01-08 2021-10-15 创芯国际生物科技(广州)有限公司 一种用于卵巢癌组织3d培养的培养基
KR20210133996A (ko) * 2019-02-24 2021-11-08 가미다-셀 리미티드 치료법에 사용하는 세포 조성물을 생성하기 위한 감마델타 t 세포의 귀소 및 체류 방법
EP3959304A4 (en) * 2019-04-26 2023-01-25 The Regents Of The University Of Colorado, A Body Corporate GENERATION OF FUNCTIONAL AND PATIENT-SPECIFIC THYMUS TISSUE IN VIVO FROM INDUCED PLURIPOTENTS STEM CELLS
WO2020223381A2 (en) * 2019-04-29 2020-11-05 Biorestorative Therapies, Inc. Non-naturally occuring three-dimensional (3d) brown adipose-derived stem cell aggregates, and methods of generating and using the same
CN110106144B (zh) * 2019-05-17 2021-10-08 苏州大学 一种诱导造血干细胞向前t系细胞分化的方法和试剂盒
AU2020283048A1 (en) 2019-05-31 2021-12-23 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
US12497597B2 (en) 2019-05-31 2025-12-16 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2020252303A1 (en) * 2019-06-12 2020-12-17 The Regents Of The University Of California Engineered off-the-shelf immune cells and methods of use thereof
WO2020264019A1 (en) * 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
WO2021006316A1 (ja) * 2019-07-10 2021-01-14 国立研究開発法人国立がん研究センター がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー
GB201911958D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd Methods of t cell production
CA3150095A1 (en) * 2019-09-06 2021-03-11 Shirley O'dea IMMUNE CELL ENGINEERING FOR EX VIVO CELLULAR THERAPY APPLICATIONS
CN112500492B (zh) * 2019-09-13 2023-08-04 中国科学院分子细胞科学卓越创新中心 一种嵌合抗原受体及其用途
CN110499288A (zh) * 2019-09-17 2019-11-26 青岛华赛伯曼医学细胞生物有限公司 体外诱导造血干细胞向胸腺t细胞分化的试剂盒及其应用
KR102081418B1 (ko) * 2019-09-24 2020-05-26 주식회사 이뮤니스바이오 말초혈액단핵구 유래 조절 t 세포 배양용 조성물 및 이를 이용한 조절 t 세포 배양방법
CN110872575A (zh) * 2019-10-21 2020-03-10 中冠赛尔生物科技(北京)有限公司 一种iNKT细胞的体外扩增方法
CN114729318B (zh) * 2019-11-01 2025-03-11 国立大学法人京都大学 T细胞的制备方法
US20220362300A1 (en) * 2019-11-05 2022-11-17 City Of Hope Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof
WO2021110908A1 (en) 2019-12-04 2021-06-10 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Device and process for tissue-engineering and regenerative medicine
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
EP4165190A4 (en) * 2020-06-12 2024-09-25 Adoc Ssf, Llc COMPOSITIONS AND METHODS FOR THE PRODUCTION OF AUTOLOGOUS T-CELL THERAPIES
CN111849913B (zh) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 工程化免疫细胞及其用途
UY39373A (es) 2020-08-10 2022-02-25 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería
WO2022083667A1 (en) * 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Polypeptides comprising a vaccine specific tcr and a chimeric antigen receptor and uses thereof
AU2021368649A1 (en) * 2020-10-28 2023-04-20 Sangamo Therapeutics, Inc. Generation of CD4
US20220211757A1 (en) * 2020-12-28 2022-07-07 The Regents Of The University Of California Engineered gamma delta t cells and methods of making and using thereof
WO2022159866A2 (en) * 2021-01-25 2022-07-28 The Regents Of The University Of California Methods and compositions for the labeling and selection of antigen-specific t-cells
WO2022235482A1 (en) * 2021-05-03 2022-11-10 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
WO2022238890A1 (en) * 2021-05-10 2022-11-17 Bazaz Zohre Method of producing antibodies from single plasma cells
WO2022241232A1 (en) * 2021-05-14 2022-11-17 Appia Bio, Inc. Production of engineered t cells from stem cells
CA3213581A1 (en) * 2021-05-25 2022-12-01 Kai Ling LIANG Generating t cell precursors via agonizing tumor necrosis factor receptor 2
CN117957313A (zh) * 2021-07-19 2024-04-30 修复免疫股份有限公司 从多能干细胞生产免疫细胞群的方法
CN117836405A (zh) * 2021-08-13 2024-04-05 先声创新公司 三维培养多能干细胞产生造血干细胞
US20240400993A1 (en) 2021-09-27 2024-12-05 Kyoto University Method for producing t cell
CN118871572A (zh) * 2021-10-14 2024-10-29 阿彼雅生物有限公司 使用多种t细胞受体对干细胞t细胞进行工程化
US20250195655A1 (en) * 2022-02-04 2025-06-19 Kyoto University T cell production method
CN119256076A (zh) 2022-03-23 2025-01-03 国立大学法人京都大学 用于产生调节性t细胞的方法
CN114807031A (zh) * 2022-05-13 2022-07-29 山东赛恩福干细胞工程集团有限公司 一种人外周血免疫细胞库和干细胞库的构建方法
CN115125203B (zh) * 2022-07-08 2023-10-27 珠海贝索细胞科学技术有限公司 一种Th2细胞体外培养方法
EP4558621A1 (en) * 2022-07-18 2025-05-28 The Children's Medical Center Corporation Methods of t cell differentiation and compositions thereof
CN115181730B (zh) * 2022-07-29 2023-05-16 创芯国际生物科技(广州)有限公司 一种胃间质瘤类器官培养基及培养方法
WO2024059733A2 (en) * 2022-09-14 2024-03-21 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
CN120112629A (zh) 2022-09-26 2025-06-06 国立大学法人京都大学 T细胞产生方法
EP4608977A1 (en) * 2022-10-28 2025-09-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for accelerated production of thymic cells from pluripotent stem cells
JP2025538256A (ja) * 2022-11-23 2025-11-26 ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション ヒト血清アルブミンを用いた免疫抑制性ｔ細胞の大量生産方法
KR20250143327A (ko) * 2023-02-08 2025-10-01 클레이드 쎄라퓨틱스 인코포레이티드 Cd4+ 및 cd8+ 단일 양성 t 세포 및 이를 생성하기 위한 조성물 및 방법
CN116622632A (zh) * 2023-05-29 2023-08-22 广州市妇女儿童医疗中心 Cd4 temra在诊断孤独症共病癫痫中的应用
WO2024262610A1 (ja) 2023-06-21 2024-12-26 国立研究開発法人国立国際医療研究センター 培地並びに血球系細胞のクローン及びその製造方法
WO2025030082A1 (en) * 2023-08-02 2025-02-06 The Broad Institute, Inc. Compositions and methods for activation and maturation of immune cells
GB202312988D0 (en) * 2023-08-25 2023-10-11 Francis Crick Institute Ltd Thymic organoids
WO2025171338A1 (en) * 2024-02-09 2025-08-14 Cedars-Sinai Medical Center Episomal reprogramming of isolated cell fraction from cord blood units and generation of induced pluripotent stem cells
WO2025261952A1 (en) * 2024-06-17 2025-12-26 Universiteit Gent Production of unconventional t cells
CN118406649B (zh) * 2024-07-02 2024-09-17 苏州依科赛生物科技股份有限公司 一种cik细胞无血清培养基及其用途

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
KR940702451A (ko) 1991-09-06 1994-08-20 고야 다다시 4-아미로(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
WO1994000977A1 (fr) 1992-07-07 1994-01-20 Japan Tobacco Inc. Procede de transformation d'une monocotyledone
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5728581A (en) 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US20030059913A1 (en) 1995-11-20 2003-03-27 Walter Weyler Novel Microorganisms with ability to degrade indole and novel enzymes therefrom
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
US20030044978A1 (en) 1998-02-05 2003-03-06 Novartis Corporation Expanded and genetically modified populations of human hematopoietic stem cells
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US20020168766A1 (en) 2000-01-11 2002-11-14 Gold Joseph D. Genetically altered human pluripotent stem cells
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
AU1778001A (en) * 1999-11-17 2001-05-30 University Of Rochester Human ex vivo immune system
EP1259592A1 (en) * 2000-01-11 2002-11-27 Maxygen, Inc. Monocyte-derived dendritic cell subsets
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
WO2001088100A1 (en) 2000-05-16 2001-11-22 Kyowa Hakko Kogyo Co., Ltd. Novel method of inducing the differentiation of embryonic stem cells into ectodermal cells and use thereof
JP5943533B2 (ja) 2000-05-17 2016-07-06 アステリアス バイオセラピューティクス インコーポレイテッド 神経前駆細胞の集団
AU3929402A (en) 2000-11-22 2002-06-11 Geron Corp Tolerizing allografts of pluripotent stem cells
JP2002184539A (ja) 2000-12-14 2002-06-28 Auto Network Gijutsu Kenkyusho:Kk コネクタ
CA2441501C (en) 2001-03-23 2010-09-14 Bayer Corporation Rho-kinase inhibitors
WO2002076976A2 (en) 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors
CA2351156A1 (en) 2001-07-04 2003-01-04 Peter W. Zandstra A bioprocess for the generation of pluripotent cell derived cells and tissues
GB2393734B (en) 2001-07-12 2005-07-27 Geron Corp Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
JP2003097552A (ja) 2001-09-21 2003-04-03 Nsk Ltd 摩擦付加装置および直動案内装置
US20030062225A1 (en) 2001-10-03 2003-04-03 Stucky Paul A. Elevator load bearing assembly having a detectable element that is indicative of local strain
CN102008503B (zh) 2001-12-07 2018-10-09 阿斯特利亚斯生物治疗股份公司 人胚胎干细胞衍生的造血细胞
ES2305435T3 (es) 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
CA2473510A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
WO2003062404A1 (en) 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
WO2004098490A2 (en) 2002-05-17 2004-11-18 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
US20040039796A1 (en) 2002-08-08 2004-02-26 Virtual Radio, Inc. Personalized cyber disk jockey and Internet radio advertising
WO2004039796A1 (de) 2002-10-28 2004-05-13 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
US7986994B2 (en) 2002-12-04 2011-07-26 Medtronic, Inc. Method and apparatus for detecting change in intrathoracic electrical impedance
US7575925B2 (en) * 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
EP1649007A4 (en) 2003-07-17 2008-05-14 Gamida Cell Ltd PROCESS FOR THE EX-VIVO EXPANSION OF STEM / PROVIDER CELLS
US7795404B1 (en) 2003-08-08 2010-09-14 Five Prime Therapeutics, Inc. Human soluble notch receptor ligands
AU2004269395A1 (en) 2003-08-27 2005-03-10 Stemcells California, Inc. Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations
WO2005070120A2 (en) * 2004-01-09 2005-08-04 Serologicals Investment Company, Inc. Cell culture media
WO2005080554A1 (ja) 2004-02-23 2005-09-01 Kyoto University 胚性幹細胞の分化調節方法
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
JP5141016B2 (ja) 2004-06-18 2013-02-13 独立行政法人理化学研究所 無血清浮遊培養による胚性幹細胞の神経分化誘導法
US20080038820A1 (en) 2004-06-22 2008-02-14 Rudy-Reil Diane E Induction of pluripotent stem cells into mesodermal lineages
ES2624586T3 (es) 2004-09-08 2017-07-17 Wisconsin Alumni Research Foundation Cultivo de células madre embrionarias humanas
US20080254003A1 (en) 2004-12-22 2008-10-16 Robert Passier Differentiation of Human Embryonic Stem Cells and Cardiomyocytes and Cardiomyocyte Progenitors Derived Therefrom
WO2007027226A2 (en) 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
EP2327774A3 (en) 2005-10-18 2011-09-28 Precision Biosciences Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
EP1815863A1 (en) 2006-02-03 2007-08-08 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of TLR3 agonists for the treatment of neurodegenerative disorders
WO2007113505A2 (en) 2006-03-30 2007-10-11 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors. and uses thereof
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008094597A2 (en) 2007-01-30 2008-08-07 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
WO2009035522A1 (en) 2007-09-14 2009-03-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US10350243B2 (en) * 2008-01-30 2019-07-16 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors
WO2009097140A1 (en) * 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
US8603810B2 (en) * 2008-05-09 2013-12-10 Agency For Science, Technology And Research T-cell having a T-cell receptor that recognizes epitope HBC18-27 of hepatitis B viral core antigen
DE102008040322A1 (de) 2008-07-10 2010-09-16 Dilo Trading Ag Energiespeicher-Kreislaufsystem unter Verwendung von Lithium-Ionen-Zellen
WO2010030947A1 (en) 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing t cells
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
CA2753679C (en) 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
EP2539441B1 (en) 2010-02-22 2016-09-28 Université Pierre et Marie Curie (Paris 6) Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage
GB201006768D0 (en) 2010-04-22 2010-06-09 Cancer Rec Tech Ltd Method for obtaining dendritic cells
CA2802721C (en) 2010-06-25 2015-08-18 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
JP2016510594A (ja) 2013-03-05 2016-04-11 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Ｔリンパ球におけるヘパラナーゼの発現
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
US9409760B1 (en) 2013-12-05 2016-08-09 Paul Lichtefeld, Sr. Fluid dispenser
US9410501B2 (en) 2014-04-25 2016-08-09 Rohr, Inc. Translating sleeve actuation system and apparatus
US11680244B2 (en) 2015-05-20 2023-06-20 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
IL258899B2 (en) * 2015-10-30 2024-03-01 Univ California Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells

Also Published As

Publication number Publication date
AU2023202195A1 (en) 2023-05-11
CA3003145C (en) 2025-11-18
US20190231817A1 (en) 2019-08-01
CN108463548A (zh) 2018-08-28
JP6983771B2 (ja) 2021-12-17
EP3368660A4 (en) 2019-04-24
MX2024012982A (es) 2024-11-08
KR20180092951A (ko) 2018-08-20
US20250346855A1 (en) 2025-11-13
US11154573B2 (en) 2021-10-26
IL258899A (en) 2018-06-28
US12297452B2 (en) 2025-05-13
BR112018008648A2 (pt) 2018-11-27
WO2017075389A1 (en) 2017-05-04
TWI812584B (zh) 2023-08-21
EP3368660A1 (en) 2018-09-05
AU2023202195B2 (en) 2025-06-05
WO2017075389A8 (en) 2018-05-24
CN108463548B (zh) 2023-04-18
JP2018533364A (ja) 2018-11-15
NZ742915A (en) 2024-02-23
IL258899B2 (en) 2024-03-01
US20220096553A1 (en) 2022-03-31
TW202344686A (zh) 2023-11-16
SG11201803419PA (en) 2018-05-30
TW201730334A (zh) 2017-09-01
JP7402211B2 (ja) 2023-12-20
CA3003145A1 (en) 2017-05-04
JP2022033812A (ja) 2022-03-02
IL258899B1 (en) 2023-11-01
AU2016343682A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
MX2018005274A (es) Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
MX2020006689A (es) Composiciones de vcar y metodos de uso.
CL2018002140A1 (es) Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos
MX2019000180A (es) Composiciones de células t para la inmunoterapia.
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
MX361760B (es) Receptores de celulas t con afinidad aumentada y metodos para hacer los mismos.
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MY208943A (en) Taurine supplemented cell culture medium and methods of use
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX2020000621A (es) Composiciones para usarse en inmunomodulacion.
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
MX2017010159A (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.
MX388202B (es) Métodos para generar productos de esmalte in vitro.
MX2021009967A (es) Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
MX386520B (es) Polimorfos de sepiapterina y sales de los mismos.
BR112016028512A2 (pt) métodos de cultivo por perfusão e seu uso
MX2018006373A (es) Produccion de virus en cultivos celulares.
MX2017003651A (es) Métodos de establecimiento de bancos de células de densidad ultra-alta.
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
EA201791233A1 (ru) Материал стволовых клеток и способ его получения
CL2010000774A1 (es) Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso.